Ymana 15 mg filmom obložene

Glavna informacija

  • Trgovački naziv:
  • Ymana 15 mg filmom obložene tablete
  • Doziranje:
  • 15 mg
  • Farmaceutski oblik:
  • filmom obložena tableta
  • Sastav:
  • Urbroj: jedna filmom obložena tableta sadrži 15 mg memantinklorida, što odgovara 12,46 mg memantina
  • Tip recepta:
  • na recept, u ljekarni ograničeni recept
  • Koristi za:
  • Ljudi
  • Vrsta lijekova:
  • alopatski lijek
  • Proizveden od:
  • Alkaloid - INT d.o.o., Ljubljana, Slovenija

Dokument

Lokalizacija

  • Na raspolaganju u:
  • Ymana 15 mg filmom obložene tablete
    Hrvatska
  • Jezik:
  • hrvatski

Terapeutski informacija

  • Proizvod sažetak:
  • Pakiranje: 7 tableta u blisteru, u kutiji [HR-H-395469294-01] Urbroj: 381-12-01/70-14-05

Druge informacije

Status

  • Izvor:
  • HALMED Agencija za lijekove i medicinske proizvode - Agency for medicinal products and medical devices of Croatia
  • Broj odobrenja:
  • HR-H-395469294
  • Datum autorizacije:
  • 09-09-2014
  • Zadnje ažuriranje:
  • 05-06-2018

Uputu o lijeku

UPUTA O LIJEKU: INFORMACIJA ZA KORISNIKA

YMANA 5 mg filmom obložene tablete

YMANA 10 mg filmom obložene tablete

YMANA 15 mg filmom obložene tablete

YMANA 20 mg filmom obložene tablete

(memantinklorid)

Pažljivo pročitajte cijelu uputu prije nego počnete uzimati ovaj lijek jer sadrži Vama

važne podatke.

Sačuvajte ovu uputu. Možda ćete je trebati ponovno pročitati.

Ako imate dodatnih pitanja, obratite se svom liječniku ili ljekarniku.

Ovaj je lijek propisan samo Vama. Nemojte ga davati drugima. Može im naškoditi, čak i

ako su njihovi znakovi bolesti jednaki Vašima.

Ako primijetite bilo koju nuspojavu, potrebno je obavijestiti liječnika, ili ljekarnika. To

uključuje i svaku moguću nuspojavu koja nije navedena u ovoj uputi. Pogledajte dio 4.

Što se nalazi u ovoj uputi:

Što je Ymana i za što se koristi

Što morate znati prije nego počnete uzimati Ymanu

Kako uzimati Ymanu

Moguće nuspojave

Kako čuvati Ymanu

Sadržaj pakiranja i druge informacije

1.

Što je Ymana i za što se koristi

Ymana se ubraja u skupinu lijekova poznatih kao lijekovi protiv demencije.

Gubitak pamćenja u Alzheimerovoj bolesti pripisuje se poremećaju prijenosa signala u mozgu.

Mozak sadržava takozvane N-metil-D-aspartat (NMDA) receptore koji su uključeni u prijenos

živčanih signala važnih u učenju i pamćenju. Ymana spada u skupinu lijekova poznatih kao

antagonisti NMDA receptora. Ymana djeluje na navedene NMDA receptore poboljšavajući

prijenos živčanih signala i pamćenje

- Ymana se koristi za liječenje bolesnika s umjerenom do teškom Alzheimerovom bolešću.

2.

Što morate znati prije nego počnete uzimati Ymanu

Nemojte uzimati Ymanu

- ako ste alergični na memantinklorid ili bilo koji drugi sastojak ovog lijeka (naveden u dijelu 6).

Ako niste sigurni odnosi li se gore navedeno na Vas, razgovarajte s Vašim liječnikom ili

ljekarnikom prije nego što uzmete Ymana tablete.

H A L M E D

09 - 09 - 2014

O D O B R E N O

Upozorenja i mjere opreza

Obratite se svom liječniku ili ljekarniku prije nego počnete uzimati Ymanu:

ako u anamnezi imate epileptičke napadaje,

ako ste nedavno imali infarkt miokarda (srčani udar), ili ako bolujete od kongestivnog

zatajenja srca ili nekontrolirane hipertenzije (povišeni krvni tlak).

U tim slučajevima liječenje mora biti pažljivo nadzirano, a Vaš liječnik treba redovito ponovno

procjenjivati kliničku korist od uzimanja Ymane.

Ako imate oštećenje funkcije bubrega (problemi s bubrezima), liječnik treba pažljivo pratiti

funkciju Vaših bubrega i ovisno o njoj, prilagoditi dozu memantina, ako je to potrebno.

Trebalo bi izbjegavati istodobnu primjenu lijekova koji se zovu amantadin (za liječenje

Parkinsonove bolesti), ketamin (tvar koja se obično koristi kao anestetik), dekstrometorfan

(obično se koristi za liječenje kašlja) i ostalih antagonista NMDA.

Djeca i adolescenti

Ymana se ne preporučuje za djecu i adolescente mlađe od 18 godina.

Drugi lijekovi i Ymana

Obavijestite svog liječnika ili ljekarnika ako uzimate ili ste nedavno uzeli ili biste mogli uzeti

bilo koje druge lijekove.

Posebice, Ymana može promijeniti učinak sljedećih lijekova te će liječnik možda morati

prilagoditi njihovu dozu:

amantadina, ketamina, dekstrometorfana;

dantrolena, baklofena;

cimetidina, ranitidina, prokainamida, kinidina, kinina, nikotina;

hidroklorotiazida (ili bilo koja kombinacija s hidroklorotiazidom);

antikolinergika (lijekovi koje se uglavnom koriste za liječenje poremećaja kretanja ili

crijevnih grčeva);

antikonvulziva (lijekovi koji se koriste za sprječavanje i ublažavanje napadaja);

barbiturata (lijekovi koji se uglavnom koriste za uspavljivanje);

dopaminergičkih agonista (lijekovi kao što su L-dopa, bromokriptin);

neuroleptika (lijekovi koji se koriste za liječenje mentalnih poremećaj

oralnih antikoagulansa.

Ako idete u bolnicu, obavijestite svog liječnika da uzimate Ymanu.

Ymana s hranom, pićem i alkoholom

Ako ste nedavno promijenili, ili namjeravate značajno promijeniti svoj način prehrane (npr.

prijeći s normalne prehrane na strogu vegetarijansku prehranu), ili ako bolujete od renalne

tubularne acidoze (RTA - izrazito povećana količina tvari koje tvore kiseline u krvi zbog

H A L M E D

09 - 09 - 2014

O D O B R E N O

poremećaja rada bubrega (slaba funkcija bubrega)) ili teških infekcija mokraćnih putova, trebali

biste obavijestiti svog liječnika, jer će Vam liječnik možda morati prilagoditi dozu lijeka.

Trudnoća, dojenje i plodnost

Ako ste trudni ili dojite, mislite da biste mogli biti trudni ili planirate imati dijete, obratite se

svom liječniku ili ljekarniku za savjet prije nego uzmete ovaj lijek.

Ne preporučuje se primjena Ymane u trudnica.

Žene koje uzimaju Ymana tablete ne bi trebale dojiti.

Upravljanje vozilima i strojevima

Liječnik će Vam reći dopušta li Vam Vaša bolest sigurno upravljanje vozilima i rad sa

strojevima. Ymana također može promijeniti Vašu sposobnost reagiranja, što čini upravljanje

vozilima i rad sa strojevima neprikladnima.

3.

Kako uzimati Ymanu

Uvijek uzimajte ovaj lijek točno onako kako Vam je rekao Vaš liječnik. Provjerite s Vašim

liječnikom ili ljekarnikom ako niste sigurni.

Doziranje

Preporučena doza Ymane za odrasle i starije bolesnike je 20 mg jedanput na dan. Kako bi se

smanjio rizik od nuspojava ta doza se postiže postupno, pridržavajući se sljedeće sheme dnevnog

liječenja:

1. tjedan (1. – 7. dan)

5 mg dnevno

2. tjedan (8. – 14. dan)

10 mg dnevno

3. tjedan (15. – 21. dan)

15 mg dnevno

4. tjedan i nadalje

20 mg dnevno

Uobičajena početna doza iznosi 5 mg jedanput na dan tijekom prvog tjedna liječenja. Ova doza

se povećava na 10 mg jedanput na dan u drugom tjednu te na 15 mg jedanput na dan u trećem

tjednu. Od četvrtog tjedna nadalje uobičajena doza je 20 mg jedanput na dan.

Doza održavanja

Preporučena dnevna doza je 20 mg jedanput na dan.

Za nastavak liječenja posavjetujte se sa svojim liječnikom.

Doziranje u bolesnika s oštećenom funkcijom bubrega

Ako imate oštećenu funkciju bubrega, liječnik će odlučiti o dozi koja odgovara Vašem stanju. U

tom slučaju liječnik bi trebao u određenim razmacima nadzirati funkciju bubrega.

H A L M E D

09 - 09 - 2014

O D O B R E N O

Način primjene

Ymana tablete treba primjenjivati kroz usta jedanput na dan. Kako biste imali korist od ovog

lijeka, trebate ga uzimati redovito svaki dan, u isto doba dana. Tablete treba progutati s malo

vode. Tablete se mogu uzimati s hranom ili bez nje.

Tablete Ymana od 10 mg i 20 mg mogu se razdijeliti na jednake doze.

Trajanje liječenja

Nastavite uzimati Ymanu onoliko dugo koliko od nje imate koristi. Vaš liječnik treba redovito

procjenjivati Vaše liječenje.

Ako uzmete više Ymana tableta nego što ste trebali

Ako ste uzeli preveliku dozu Ymana tableta, javite se Vašem liječniku za savjet, jer bi Vam

mogla biti potrebna medicinska pomoć.

Općenito, uzimanje previše Ymana tableta ne bi Vam trebalo naškoditi. Mogli bi Vam se javiti

izraženiji simptomi opisani u dijelu 4. „Moguće nuspojave“.

Ako ste zaboravili uzeti Ymana tablete

Ako ustanovite da ste zaboravili uzeti dozu Ymana tableta, pričekajte i uzmite sljedeću

dozu u uobičajeno vrijeme.

Nemojte uzeti dvostruku dozu kako biste nadoknadili zaboravljenu dozu.

U slučaju bilo kakvih nejasnoća ili pitanja u vezi s primjenom ovog lijeka obratite se svom

liječniku ili ljekarniku.

4.

Moguće nuspojave

Kao i svi drugi lijekovi, ovaj lijek može uzrokovati nuspojave, iako se neće javiti kod svakoga.

Ako primijetite nuspojave kao što su napadaji, samoubilačke ideje i samoubilačke misli,

odmah razgovarajte sa svojim liječnikom ili ljekarnikom.

Općenito, opažene nuspojave su blage do umjerene.

Česte (javljaju se u 1 od 10 liječenih bolesnika):

glavobolja, pospanost, zatvor, povišeni rezultati testova jetrene funkcije, omaglica,

poremećaji ravnoteže, nedostatak zraka, visoki krvni tlak i preosjetljivost na lijek.

Manje česte (javljaju se u 1 od 100 liječenih bolesnika):

umor, gljivične infekcije, smetenost, halucinacije, povraća

nje, poremećaj hoda, zatajenje

srca i zgrušavanje venske krvi (tromboza/tromboembolija).

Vrlo rijetke (javljaju se kod manje od 1 od 10 000 bolesnika):

napadaji.

H A L M E D

09 - 09 - 2014

O D O B R E N O

Nepoznate učestalosti (učestalost se ne može procijeniti iz raspoloživih podataka):

upala gušterače, upala jetre (hepatitis) i psihotične reakcije.

Alzheimerova bolest se povezuje s depresijom, samoubilačkim mislima i samoubojstvom. Ovi su

događaji prijavljivani u bolesnika liječenih Ymanom.

Ako primijetite bilo koju nuspojavu, potrebno je obavijestiti liječnika ili ljekarnika. Ovo

uključuje i svaku moguću nuspojavu koja nije navedena u ovoj uputi.

Prijavljivanje nuspojava

Ako primijetite bilo koju nuspojavu, potrebno je obavijestiti liječnika ili ljekarnika.

uključuje i svaku moguću nuspojavu koja nije navedena u ovoj uputi. Nuspojave možete prijaviti

izravno putem nacionalnog sustava za prijavu nuspojava navedenog u Dodatku V.

Prijavljivanjem nuspojava možete pridonijeti u procjeni sigurnosti ovog lijeka

.

5.

Kako čuvati Ymanu

Ne čuvati na temperaturi iznad 25°C. Čuvati blistere u originalnom pakiranju radi zaštite od

svjetlosti.

Ovaj lijek čuvajte izvan pogleda i dohvata djece.

Ovaj lijek se ne smije upotrijebiti nakon isteka roka valjanosti navedenog na kartonskoj kutiji i

blisteru iza oznake „EXP“. Rok valjanosti odnosi se na zadnji dan navedenog mjeseca.

Nikada nemojte nikakve lijekove bacati u otpadne vode ili kućni otpad. Pitajte svog ljekarnika kako

baciti lijekove koje više ne koristite. Ove će mjere pomoći u očuvanju okoliša.

6.

Sadržaj pakiranja i druge informacije

Što Ymana sadrži

Djelatna tvar je memantinklorid.

Svaka 5 mg filmom obložena tableta sadržava 5 mg memantinklorida, što odgovara 4,15 mg

memantina.

Svaka 10 mg filmom obložena tableta sadržava 10 mg memantinklorida, što odgovara 8,31 mg

memantina.

Svaka 15 mg filmom obložena tableta sadržava 15 mg memantinklorida, što odgovara 12,46 mg

memantina.

Svaka 20 mg filmom obložena tableta sadržava 20 mg memantinklorida, što odgovara 16,62 mg

memantina.

Drugi sastojci su:

Tabletna jezgra

: celuloza mikrokristalična, silicirana; karmelozanatrij, umrežena; talk;

magnezijev stearat.

Film-ovojnica:

hipromeloza; makrogol 400 i titanijev dioksid (E171).

Dodatno za tablete od 15 mg, željezov oksid, žuti (E172) u film-ovojnici.

H A L M E D

09 - 09 - 2014

O D O B R E N O

Dodatno za tablete od 20 mg, željezov oksid, crveni (E172) u film-ovojnici.

Kako Ymana izgleda i sadržaj pakiranja

Ymana 5 mg su bijele do gotovo bijele, bikonveksne filmom obložene tablete oblika kapsule, s

utisnutom oznakom “5” na jednoj strani i ravne na drugoj strani. Dimenzije svake tablete su

približno 10 x 4 mm.

Ymana 10 mg su bijele do gotovo bijele filmom obložene tablete ovalnog oblika, s utisnutom

oznakom “10” na jednoj strani i razdjelnom crtom na drugoj strani. Dimenzije svake tablete su

približno 11 x 6 mm.

Ymana 15 mg su žućkaste filmom obložene tablete ovalnog oblika, s utisnutom oznakom “15”

na jednoj strani i ravne na drugoj strani. Dimenzije svake tablete su približno 14 x 7 mm.

Ymana 20 mg su smećkasto ružičaste filmom obložene tablete ovalnog oblika, s utisnutom

oznakom “20” na jednoj strani i razdjelnom crtom na drugoj strani. Dimenzije svake tablete su

približno 14 x 7 mm.

Ymana 10 mg i 20 mg tablete mogu se razdijeliti na jednake polovice.

Pakiranje tableta od 5 mg: Al/PVC blister pakiranje sadrži 7 tableta u blister traci. Pakiranje

sadrži 7 tableta.

Pakiranja tableta od 10 mg: Al/PVC blister pakiranje sadrži 7, 10 ili 14 tableta u blister traci.

Pakiranje sadrži 7, 28 ili 30 tableta.

Pakiranje tableta od 15 mg: Al/PVC blister pakiranje sadrži 7 tableta u blister traci. Pakiranje

sadrži 7 tableta.

Pakiranja tableta od 20 mg: Al/PVC blister pakiranje sadrži 7, 10 ili 14 tableta u blister traci.

Pakiranje sadrži 7, 28 ili 30 tableta.

Nositelj odobrenja za stavljanje lijeka u promet i proizvođač

ALKALOID-INT d.o.o.

Šlandrova ulica 4

1231 Ljubljana - Črnuče

Slovenija

tel.: +386 1 300 42 90

fax: +386 1 300 42 91

e-mail: info@alkaloid.si

Za sve informacije o ovom lijeku obratite se lokalnom predstavniku nositelja odobrenja za

stavljanje lijeka u promet:

Alkaloid d.o.o.

Ulica grada Vukovara 226 F

H A L M E D

09 - 09 - 2014

O D O B R E N O

Zagreb, Hrvatska

tel. +385 1 63 11 920

fax. +385 1 63 11 922

e-mail: alkaloid@alkaloid.hr

Ovaj je lijek odobren u državama članicama Europskog ekonomskog prostora (EEA) pod

sljedećim nazivima:

Bugarska:

YMANA 5 mg; 10 mg; 15 mg; 20 mg film-coated tablets

Hrvatska:

YMANA 5 mg; 10 mg; 15 mg; 20 mg filmom obložene tablete

Slovenija:

YMANA 5 mg; 10 mg; 15 mg; 20 mg filmsko obložene tablete

Ujedinjeno Kraljevstvo:

YMANA 5 mg; 10 mg; 15 mg; 20 mg film-coated tablets

Način i mjesto izdavanja lijeka

Lijek se izdaje na recept, u ljekarni.

Ova uputa je zadnji puta revidirana u rujnu 2014

H A L M E D

09 - 09 - 2014

O D O B R E N O

20-11-2018

Mariam, Floris en Mookie beëdigd tot kinderbewindspersonen van VWS

Mariam, Floris en Mookie beëdigd tot kinderbewindspersonen van VWS

Nederland is vandaag op de Internationale Dag van de Rechten van het Kind drie bewindspersonen rijker. Mariam Yousfi (13 jaar) en Floris Vooren (13 jaar) zijn door ministers Hugo de Jonge en Bruno Bruins benoemd tot kinderminister en Mookie Saluna (15 jaar) is door staatssecretaris Paul Blokhuis benoemd tot kinderstaatssecretaris. De kinderbewindspersonen zullen een jaar lang het ministerie van Volksgezondheid, Welzijn en Sport (VWS) met slimme tips en praktische adviezen helpen het beleid beter en kindv...

Netherlands - Ministerie van Volksgezondheid, Welzijn en Sport

16-11-2018

Setting of an import tolerance for pyraclostrobin in rice

Setting of an import tolerance for pyraclostrobin in rice

Published on: Thu, 15 Nov 2018 In accordance with Article 6 of Regulation (EC) No 396/2005, the applicant BASF SE submitted a request to the competent national authority in Germany to set an import tolerance for the active substance pyraclostrobin in rice. The data submitted in support of the request were found to be sufficient to derive a maximum residue level (MRL) proposal for rice. Based on the risk assessment results, EFSA concluded that the short‐term intake of residues resulting from the use of p...

Europe - EFSA - European Food Safety Authority Publications

16-11-2018

Evaluation of confirmatory data following the Article 12 MRL review for pyraclostrobin

Evaluation of confirmatory data following the Article 12 MRL review for pyraclostrobin

Published on: Thu, 15 Nov 2018 The applicant BASF SE submitted a request to the competent national authority in Germany to evaluate the confirmatory data that were identified for pyraclostrobin in the framework of the MRL review under Article 12 of Regulation (EC) No 396/2005 as not available. To address the data gaps, residues trials supporting the existing use of pyraclostrobin on table grapes authorised in southern EU Member States and an analytical method for analysing residues of pyraclostrobin in ...

Europe - EFSA - European Food Safety Authority Publications

7-11-2018

Kadesh Incorporation Issues Voluntary Nationwide Recall of Puriton Eye Relief Drops Due to Non-Sterile Production Conditions

Kadesh Incorporation Issues Voluntary Nationwide Recall of Puriton Eye Relief Drops Due to Non-Sterile Production Conditions

Kadesh, Inc. of Garden Grove, CA is voluntarily recalling all lots of Puriton Eye Relief Drops, 0.5 oz. (15ml) bottle, UPC 7 36972 1679 0, to the consumer level. During a recent FDA inspection, investigators observed that ophthalmic drugs, which are required to be sterile, are manufactured without necessary production controls and conditions to assure sterility.

FDA - U.S. Food and Drug Administration

20-10-2018

Scientific Opinion of Flavouring Group Evaluation 411 (FGE.411): 2‐(4‐methylphenoxy)‐N‐(1H‐pyrazol‐3‐yl)‐N‐(thiophen‐2‐ylmethyl)acetamide from chemical group 30 (miscellaneous substances)

Scientific Opinion of Flavouring Group Evaluation 411 (FGE.411): 2‐(4‐methylphenoxy)‐N‐(1H‐pyrazol‐3‐yl)‐N‐(thiophen‐2‐ylmethyl)acetamide from chemical group 30 (miscellaneous substances)

Published on: Fri, 19 Oct 2018 00:00:00 +0200 EFSA was requested to deliver a scientific opinion on the implications for human health of the flavouring substance 2‐(4‐methylphenoxy)‐N‐(1H‐pyrazol‐3‐yl)‐N‐(thiophen‐2‐ylmethyl)acetamide [FL‐no: 16.133], in the Flavouring Group Evaluation 411 (FGE.411), according to Regulation (EC) No 1331/2008 of the European Parliament and of the Council. The substance has not been reported to occur in natural source materials of botanical or animal origin. It is intende...

Europe - EFSA - European Food Safety Authority Publications

17-10-2018

Faribault Foods, Inc. Announces Voluntary Recall of a Limited Quantity of S&W Brand White Beans Due to the Presence of Undeclared (Sulfites)

Faribault Foods, Inc. Announces Voluntary Recall of a Limited Quantity of S&W Brand White Beans Due to the Presence of Undeclared (Sulfites)

Faribault Foods, Inc. of Faribault, MN is recalling its 15 ounce S&W White Beans because it contains undeclared sulfites. People who have an allergy or severe sensitivity to sulfites run the risk of serious or life-threatening allergic reaction if they consume this product.

FDA - U.S. Food and Drug Administration

17-10-2018

Enforcement Report for the Week of October 17, 2018

Enforcement Report for the Week of October 17, 2018

Recently Updated Records for the Week of October 17, 2018 Last Modified Date: Monday, October 15, 2018

FDA - U.S. Food and Drug Administration

16-10-2018

October 15, 2018: Leader of Fraudulent Prescription Conspiracy Sentenced to Six Years in Prison

October 15, 2018: Leader of Fraudulent Prescription Conspiracy Sentenced to Six Years in Prison

October 15, 2018: Leader of Fraudulent Prescription Conspiracy Sentenced to Six Years in Prison

FDA - U.S. Food and Drug Administration

16-10-2018

October 15, 2018: Four Men and Seven Companies Indicted for Billion-Dollar Telemedicine Fraud Conspiracy, Telemedicine Company and CEO Plead Guilty in Two Fraud Schemes

October 15, 2018: Four Men and Seven Companies Indicted for Billion-Dollar Telemedicine Fraud Conspiracy, Telemedicine Company and CEO Plead Guilty in Two Fraud Schemes

October 15, 2018: Four Men and Seven Companies Indicted for Billion-Dollar Telemedicine Fraud Conspiracy, Telemedicine Company and CEO Plead Guilty in Two Fraud Schemes

FDA - U.S. Food and Drug Administration

16-10-2018

Pest categorisation of Cronartium harknessii, Cronartium kurilense and Cronartium sahoanum

Pest categorisation of Cronartium harknessii, Cronartium kurilense and Cronartium sahoanum

Published on: Mon, 15 Oct 2018 00:00:00 +0200 Following a request from the European Commission, the EFSA Panel on Plant Health performed a pest categorisation of Cronartium harknessii, Cronartium kurilense and Cronartium sahoanum, which are well‐defined and distinguishable tree fungal pathogens of the family Cronartiaceae. In 2018, these species were moved from the genus Endocronartium to the genus Cronartium. These pathogens are not known to be present in the EU and are regulated in Council Directive 2...

Europe - EFSA - European Food Safety Authority Publications

16-10-2018

Modification of the existing maximum residue levels for mepiquat in cotton seeds and animal commodities

Modification of the existing maximum residue levels for mepiquat in cotton seeds and animal commodities

Published on: Mon, 15 Oct 2018 00:00:00 +0200 In accordance with Article 6 of Regulation (EC) No 396/2005, the applicant, BASF SE, submitted an application to the competent national authority in Greece to modify the existing maximum residue level (MRL) for the active substance mepiquat in cotton seeds. The data submitted in support of the application were found to be sufficient to derive a MRL proposal for cotton seeds and the previously derived MRL proposals for animal commodities were found to be stil...

Europe - EFSA - European Food Safety Authority Publications

16-10-2018

Assessment of low pathogenic avian influenza virus transmission via raw poultry meat and raw table eggs

Assessment of low pathogenic avian influenza virus transmission via raw poultry meat and raw table eggs

Published on: Mon, 15 Oct 2018 00:00:00 +0200 A rapid qualitative assessment has been done by performing a theoretical analysis on the transmission of low pathogenic avian influenza (LPAI) via fresh meat from poultry reared or kept in captivity for the production of meat (raw poultry meat) or raw table eggs. A predetermined transmission pathway followed a number of steps from a commercial or non‐commercial poultry establishment within the EU exposed to LPAI virus (LPAIV) to the onward virus transmission...

Europe - EFSA - European Food Safety Authority Publications

16-10-2018

Pest categorisation of Melampsora farlowii

Pest categorisation of Melampsora farlowii

Published on: Mon, 15 Oct 2018 00:00:00 +0200 Following a request from the European Commission, the EFSA Panel on Plant Health performed a pest categorisation of Melampsora farlowii, a well‐defined and distinguishable fungus of the family Melampsoraceae. M. farlowii is the causal agent of a leaf and twig rust of hemlocks (Tsuga spp.) in eastern North America. The pathogen is regulated in Council Directive 2000/29/EC (Annex IAI) as a harmful organism whose introduction into the EU is banned. M. farlowii ...

Europe - EFSA - European Food Safety Authority Publications

16-10-2018

Evaluation of confirmatory data following the Article 12 MRL review for teflubenzuron

Evaluation of confirmatory data following the Article 12 MRL review for teflubenzuron

Published on: Mon, 15 Oct 2018 00:00:00 +0200 The applicant BASF Agro BV submitted a request to the competent national authority in United Kingdom to evaluate the confirmatory data that were identified for teflubenzuron in the framework of the maximum residue level (MRL) review under Article 12 of Regulation (EC) No 396/2005 as not available. To address the data gaps, a new metabolism study on leafy crops, a study investigating the nature of residues under standard hydrolytic conditions and a validated ...

Europe - EFSA - European Food Safety Authority Publications

3-10-2018

Sportminister Bruno Bruins brengt verrassingsbezoek aan Talent TeamNL in Buenos Aires

Sportminister Bruno Bruins brengt verrassingsbezoek aan Talent TeamNL in Buenos Aires

Van 6 tot 18 oktober wordt in Buenos Aires, Argentinië, de derde editie van de Jeugd Olympische Spelen gehouden. Toptalenten uit 206 landen tussen de 15 en 18 jaar oud doen hieraan mee. Talent TeamNL bestaat uit 41 sporters die uitkomen in  19 disciplines. Minister voor Sport Bruno Bruins bracht vandaag een verrassingsbezoek aan de Nederlandse ploeg. Hij bezocht het Olympisch Dorp waar de talenten onder leiding van Chef de Mission Mark Huizinga zich voorbereiden op de Spelen die zaterdag beginnen. 

Netherlands - Ministerie van Volksgezondheid, Welzijn en Sport

28-9-2018

EpiPen and EpiPen Jr auto-injectors may stick in their carrier tube

EpiPen and EpiPen Jr auto-injectors may stick in their carrier tube

Pfizer Canada has advised Health Canada that, in a very small number of cases, some EpiPen (0.3 mg) and EpiPen Jr (0.15 mg) auto-injector devices may not slide out of their carrier tube easily, or at all. This could delay or prevent emergency treatment, possibly leading to patient disability or death.

Health Canada

28-9-2018

Avian influenza overview May – August 2018

Avian influenza overview May – August 2018

Published on: Thu, 27 Sep 2018 00:00:00 +0200 Between 16 May and 15 August 2018, three highly pathogenic avian influenza (HPAI) A(H5N8) outbreaks in poultry establishments and three HPAI A(H5N6) outbreaks in wild birds were reported in Europe. Three low pathogenic avian influenza (LPAI) outbreaks were reported in three Member States. Few HPAI and LPAI bird cases have been detected in this period of the year, in accordance with the seasonal expected pattern of LPAI and HPAI. There is no evidence to date ...

Europe - EFSA - European Food Safety Authority Publications

26-9-2018

Technical Report on the notification of syrup from Sorghum bicolor (L.) Moench as a traditional food from a third country pursuant to Article 14 of Regulation (EU) 2015/2283

Technical Report on the notification of syrup from Sorghum bicolor (L.) Moench as a traditional food from a third country pursuant to Article 14 of Regulation (EU) 2015/2283

Published on: Tue, 25 Sep 2018 00:00:00 +0200 Abstract Following a notification from Sorghum Zrt., submitted to the European Commission under Article 14 of Regulation (EU) 2015/2283 to place on the market syrup from Sorghum bicolor (L.) Moench as a traditional food from a third country (TF), and in line with Article 15(2) of that Regulation, EFSA was asked by the European Commission whether there are duly reasoned safety objections to the placing on the market of the TF within the European Union. The ap...

Europe - EFSA - European Food Safety Authority Publications

29-8-2018

Risk to human and animal health related to the presence of 4,15‐diacetoxyscirpenol in food and feed

Risk to human and animal health related to the presence of 4,15‐diacetoxyscirpenol in food and feed

Published on: Thu, 16 Aug 2018 00:00:00 +0200 4,15‐Diacetoxyscirpenol (DAS) is a mycotoxin primarily produced by Fusarium fungi and occurring predominantly in cereal grains. As requested by the European Commission, the EFSA Panel on Contaminants in the Food Chain (CONTAM) assessed the risk of DAS to human and animal health related to its presence in food and feed. Very limited information was available on toxicity and on toxicokinetics in experimental and farm animals. Due to the limitations in the avai...

Europe - EFSA - European Food Safety Authority Publications

16-8-2018

August 15, 2018: Florida Man Pleads Guilty to Scheme to Market Dietary Supplements

August 15, 2018: Florida Man Pleads Guilty to Scheme to Market Dietary Supplements

August 15, 2018: Florida Man Pleads Guilty to Scheme to Market Dietary Supplements

FDA - U.S. Food and Drug Administration

15-8-2018

Enforcement Report for the Week of August 15, 2018

Enforcement Report for the Week of August 15, 2018

Recently Updated Records for the Week of August 15, 2018 Last Modified Date: Monday, August 13, 2018

FDA - U.S. Food and Drug Administration

14-8-2018

Minister-president Rutte bij herdenking capitulatie Japan

Minister-president Rutte bij herdenking capitulatie Japan

Minister-president Rutte neemt woensdagmiddag 15 augustus 2018 deel aan de herdenking van de capitulatie van Japan op 15 augustus 1945. De herdenking vindt plaats bij het Indisch Monument in Den Haag.

Netherlands - Ministerie van Volksgezondheid, Welzijn en Sport

10-8-2018

Westminster Pharmaceuticals, LLC. Issues Voluntary Nationwide Recall of Levothyroxine and Liothyronine (Thyroid Tablets, USP) Due to Risk of Adulteration

Westminster Pharmaceuticals, LLC. Issues Voluntary Nationwide Recall of Levothyroxine and Liothyronine (Thyroid Tablets, USP) Due to Risk of Adulteration

Westminster Pharmaceuticals, LLC is voluntarily recalling all lots, within expiry, of Levothyroxine and Liothyronine (Thyroid Tablets, USP) 15 mg, 30 mg, 60 mg, 90 mg, & 120 mg to the wholesale level. These products are being recalled as a precaution because they were manufactured using active pharmaceutical ingredients that were sourced prior to the FDA’s Import Alert of Sichuan Friendly Pharmaceutical Co., Ltd., which as a result of a 2017 inspection were found to have deficiencies with Current Good Ma...

FDA - U.S. Food and Drug Administration

31-7-2018

ADM Animal Nutrition Recalls Mintrate® 36-15 Breed Right Cattle Tub - A specific lot of product may contain elevated levels of non-protein nitrogen, could harm cattle

ADM Animal Nutrition Recalls Mintrate® 36-15 Breed Right Cattle Tub - A specific lot of product may contain elevated levels of non-protein nitrogen, could harm cattle

ADM Animal Nutrition, a division of Archer Daniels Midland Company (NYSE: ADM), is recalling 200-pound tubs of Mintrate® 36-15 Breed Right Tub cattle feed, product number 54549AAA6H, because the product may contain elevated levels of non-protein nitrogen, which could be harmful to cattle. Excessive levels of non-protein nitrogen can be toxic to cattle and can cause muscle tremors (especially of face and ears), abdominal pain, bloat, frothy salivation, excessive urination, teeth grinding, incoordination, ...

FDA - U.S. Food and Drug Administration

18-7-2018

Blokhuis: jaarlijkse subsidie voor 113Zelfmoordpreventie omhoog naar 5,4 miljoen

Blokhuis: jaarlijkse subsidie voor 113Zelfmoordpreventie omhoog naar 5,4 miljoen

Staatssecretaris Paul Blokhuis (VWS) wil het aantal zelfmoorden en zelfmoordpogingen terugdringen. Om dat te bereiken geeft hij structureel 2 miljoen per jaar extra instellingssubsidie aan 113Zelfmoordpreventie. Het jaarlijkse budget van de organisatie gaat daarmee fors omhoog, van 3,4 miljoen naar 5,4 miljoen euro. Daarnaast zijn er extra middelen voor andere lopende activiteiten zoals de lokale aanpakken suïcidepreventie en onderzoek. In totaal is daar 15 miljoen mee gemoeid.

Netherlands - Ministerie van Volksgezondheid, Welzijn en Sport

17-7-2018

July 17, 2018: Former President of Cumberland Distribution, Inc. Sentenced to 15 Years in Federal Prison for $50 Million Drug Diversion Scheme

July 17, 2018: Former President of Cumberland Distribution, Inc. Sentenced to 15 Years in Federal Prison for $50 Million Drug Diversion Scheme

July 17, 2018: Former President of Cumberland Distribution, Inc. Sentenced to 15 Years in Federal Prison for $50 Million Drug Diversion Scheme

FDA - U.S. Food and Drug Administration

29-6-2018

Wish Bone Salad Dressing Issues Allergy Alert On Undeclared Milk and Egg in 15 oz. Wish-Bone House Italian Salad Dressing

Wish Bone Salad Dressing Issues Allergy Alert On Undeclared Milk and Egg in 15 oz. Wish-Bone House Italian Salad Dressing

Pinnacle Foods Inc. is voluntarily recalling a limited quantity of Wish Bone House Italian Salad Dressing 15 oz. with the health and safety of our consumers as our top priority. The recall was initiated after learning from a retail customer that a limited number of bottles were mislabeled. The product contains milk and egg, known allergens not declared on the bottle. People who have an allergy or severe sensitivity to milk or egg may run the risk of a serious or life-threatening allergic reaction if t...

FDA - U.S. Food and Drug Administration

15-11-2018

Flixabi (Samsung Bioepis NL B.V.)

Flixabi (Samsung Bioepis NL B.V.)

Flixabi (Active substance: infliximab) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)7549 of Thu, 15 Nov 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/4020/T/30

Europe -DG Health and Food Safety

15-11-2018

alitretinoin

alitretinoin

alitretinoin (Active substance: alitretinoin) - Centralised - Art 28 - (PSUR - Commission Decision (2018)7675 of Thu, 15 Nov 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/PSUSA/90/201801

Europe -DG Health and Food Safety

8-11-2018

There's only 1 week until the 2018 Patient Engagement Advisory Committee meeting. Join the @US_FDA on Nov 15 to discuss patient-generated health data from sources like social media, activity trackers, and patient-driven registries.pic.twitter.com/WkDNnXqm

There's only 1 week until the 2018 Patient Engagement Advisory Committee meeting. Join the @US_FDA on Nov 15 to discuss patient-generated health data from sources like social media, activity trackers, and patient-driven registries.pic.twitter.com/WkDNnXqm

There's only 1 week until the 2018 Patient Engagement Advisory Committee meeting. Join the @US_FDA on Nov 15 to discuss patient-generated health data from sources like social media, activity trackers, and patient-driven registries. pic.twitter.com/WkDNnXqmbw

FDA - U.S. Food and Drug Administration

31-10-2018

Imraldi (Samsung Bioepis NL B.V.)

Imraldi (Samsung Bioepis NL B.V.)

Imraldi (Active substance: adalimumab) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)7344 of Wed, 31 Oct 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/4279/T/15

Europe -DG Health and Food Safety

22-10-2018

EU/3/16/1640 (Celgene Europe B.V.)

EU/3/16/1640 (Celgene Europe B.V.)

EU/3/16/1640 (Active substance: 2-methyl-1-[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol methanesulfonate) - Transfer of orphan designation - Commission Decision (2018)6989 of Mon, 22 Oct 2018 European Medicines Agency (EMA) procedure number: EMA/OD/253/15/T/01

Europe -DG Health and Food Safety

22-10-2018

EU/3/15/1495 (Ultragenyx Netherlands B.V.)

EU/3/15/1495 (Ultragenyx Netherlands B.V.)

EU/3/15/1495 (Active substance: Triheptanoin) - Transfer of orphan designation - Commission Decision (2018)6992 of Mon, 22 Oct 2018 European Medicines Agency (EMA) procedure number: EMA/OD/007/15/T/02

Europe -DG Health and Food Safety

22-10-2018

EU/3/15/1532 (Sirius Regulatory Consulting EU Limited)

EU/3/15/1532 (Sirius Regulatory Consulting EU Limited)

EU/3/15/1532 (Active substance: Insulin human) - Transfer of orphan designation - Commission Decision (2018)6985 of Mon, 22 Oct 2018

Europe -DG Health and Food Safety

17-10-2018

Interact with experts from CDER, CBER & CDRH to learn what’s important when conducting clinical trials & preparing submissions for FDA review.

Register for FDA #CDERSBIA Clinical Investigator Training Course – November 13-15 in Silver Spring, MD.  https:

Interact with experts from CDER, CBER & CDRH to learn what’s important when conducting clinical trials & preparing submissions for FDA review. Register for FDA #CDERSBIA Clinical Investigator Training Course – November 13-15 in Silver Spring, MD. https:

Interact with experts from CDER, CBER & CDRH to learn what’s important when conducting clinical trials & preparing submissions for FDA review. Register for FDA #CDERSBIA Clinical Investigator Training Course – November 13-15 in Silver Spring, MD. https://go.usa.gov/xPqku  pic.twitter.com/EYNZANlgr9

FDA - U.S. Food and Drug Administration

15-10-2018

Riximyo (Sandoz GmbH)

Riximyo (Sandoz GmbH)

Riximyo (Active substance: rituximab) - Centralised - Yearly update - Commission Decision (2018)6811 of Mon, 15 Oct 2018

Europe -DG Health and Food Safety

1-10-2018

EU/3/16/1762 (Pharma Gateway AB)

EU/3/16/1762 (Pharma Gateway AB)

EU/3/16/1762 (Active substance: Synthetic 15-amino-acid macrocyclic peptide acylated with a polyethyleneglycol palmitoylated linker) - Transfer of orphan designation - Commission Decision (2018)6399 of Mon, 01 Oct 2018 European Medicines Agency (EMA) procedure number: EMA/OD/107/16/T/01

Europe -DG Health and Food Safety

25-9-2018

Conducting clinical trials & preparing a submission for #FDA review?

Register for #CDERSBIA’s Clinical Investigator Training Course: November 13-15 to learn about FDA regulations, scientific principles for conducting clinical trials, & more!  https://go.

Conducting clinical trials & preparing a submission for #FDA review? Register for #CDERSBIA’s Clinical Investigator Training Course: November 13-15 to learn about FDA regulations, scientific principles for conducting clinical trials, & more! https://go.

Conducting clinical trials & preparing a submission for #FDA review? Register for #CDERSBIA’s Clinical Investigator Training Course: November 13-15 to learn about FDA regulations, scientific principles for conducting clinical trials, & more! https://go.usa.gov/xPqku . pic.twitter.com/Ktqq9Slx0y

FDA - U.S. Food and Drug Administration

24-9-2018

Tomorrow, September 25th at 9:15 AM, join the #FDA for a session at #MedTechCon about our #DigitalHealth Software Precertification #FDAPrecert Pilot Program...

Tomorrow, September 25th at 9:15 AM, join the #FDA for a session at #MedTechCon about our #DigitalHealth Software Precertification #FDAPrecert Pilot Program...

Tomorrow, September 25th at 9:15 AM, join the #FDA for a session at #MedTechCon about our #DigitalHealth Software Precertification #FDAPrecert Pilot Program...

FDA - U.S. Food and Drug Administration

18-8-2018

EU/3/16/1645 (Salzman Group Ltd)

EU/3/16/1645 (Salzman Group Ltd)

EU/3/16/1645 (Active substance: Cannabidiol) - Transfer of orphan designation - Commission Decision (2018)4806 of Sat, 18 Aug 2018 European Medicines Agency (EMA) procedure number: EMA/OD/248/15/T/01

Europe -DG Health and Food Safety

15-8-2018

EU/3/18/1994 (Quality Regulatory Clinical Ireland Limited)

EU/3/18/1994 (Quality Regulatory Clinical Ireland Limited)

EU/3/18/1994 (Active substance: Ivosidenib) - Transfer of orphan designation - Commission Decision (2018)5555 of Wed, 15 Aug 2018 European Medicines Agency (EMA) procedure number: EMA/OD/172/17/T/01

Europe -DG Health and Food Safety

15-8-2018

Orbactiv (Rempex London Ltd)

Orbactiv (Rempex London Ltd)

Orbactiv (Active substance: oritavancin) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)5556 of Wed, 15 Aug 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/3785/T/20

Europe -DG Health and Food Safety

15-8-2018

Komboglyze (AstraZeneca AB)

Komboglyze (AstraZeneca AB)

Komboglyze (Active substance: saxagliptin / metformin) - Centralised - 2-Monthly update - Commission Decision (2018)5559 of Wed, 15 Aug 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/2059/WS/1289

Europe -DG Health and Food Safety

15-8-2018

Ivabradine Zentiva (Zentiva, k.s.)

Ivabradine Zentiva (Zentiva, k.s.)

Ivabradine Zentiva (Active substance: ivabradine) - Centralised - Yearly update - Commission Decision (2018)5558 of Wed, 15 Aug 2018

Europe -DG Health and Food Safety

27-7-2018

EU/3/15/1473 (Celgene Europe B.V.)

EU/3/15/1473 (Celgene Europe B.V.)

EU/3/15/1473 (Active substance: Lenalidomide) - Transfer of orphan designation - Commission Decision (2018)5042 of Fri, 27 Jul 2018 European Medicines Agency (EMA) procedure number: EMA/OD/284/14/T/01

Europe -DG Health and Food Safety

27-7-2018

EU/3/16/1635 (Leadiant GmbH)

EU/3/16/1635 (Leadiant GmbH)

EU/3/16/1635 (Active substance: N-acetyl-D-mannosamine monohydrate) - Transfer of orphan designation - Commission Decision (2018)5053 of Fri, 27 Jul 2018 European Medicines Agency (EMA) procedure number: EMA/OD/228/15/T/01

Europe -DG Health and Food Safety

10-7-2018

Corbilta (Orion Corporation)

Corbilta (Orion Corporation)

Corbilta (Active substance: levodopa / carbidopa / entacapone) - Centralised - Renewal - Commission Decision (2018)4468 of Tue, 10 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/2785/R/15

Europe -DG Health and Food Safety

27-6-2018

EU/3/15/1606 (Bayer AG)

EU/3/15/1606 (Bayer AG)

EU/3/15/1606 (Active substance: (S)-N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate) - Transfer of orphan designation - Commission Decision (2018)4094 of Wed, 27 Jun 2018 European Medicines Agency (EMA) procedure number: EMA/OD/184/15/T/02

Europe -DG Health and Food Safety

27-6-2018

EU/3/15/1460 (Eisai GmbH)

EU/3/15/1460 (Eisai GmbH)

EU/3/15/1460 (Active substance: Lenvatinib) - Transfer of orphan designation - Commission Decision (2018)4080 of Wed, 27 Jun 2018 European Medicines Agency (EMA) procedure number: EMA/OD/287/14/T/01

Europe -DG Health and Food Safety

27-6-2018

EU/3/15/1590 (Merck Europe B.V.)

EU/3/15/1590 (Merck Europe B.V.)

EU/3/15/1590 (Active substance: Recombinant human monoclonal IgG1 antibody against programmed death ligand-1) - Transfer of orphan designation - Commission Decision (2018)4088 of Wed, 27 Jun 2018 European Medicines Agency (EMA) procedure number: EMA/OD/150/15/T/02

Europe -DG Health and Food Safety